NeonMind Commences Trading Under CSE Ticker Symbol "NEON"
1/2
NeonMind Commences Trading Under CSE Ticker Symbol "NEON"
Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - NeonMind Biosciences Inc. (CSE: NEON)
("NeonMind") is pleased to announce that its common shares have today commenced trading on the Canadian
Securities Exchange (the "Exchange") under the ticker symbol "NEON". More information on NeonMind can
be found at www.neonmindbiosciences.com.
NeonMind Commences Trading Under CSE Ticker Symbol “NEON”
To view an enhanced version of this image, please visit:
https://orders.newsfilecorp.com/files/7646/71280_754b8cd704168a78_001full.jpg
NeonMind completed its oversubscribed Initial Public Offering on December 30, 2020, for gross proceeds of
$4,600,000.
NeonMind is a psychedelic drug development company. It's mission is to help people change their lives by
changing their minds, through treatment with psychedelics.
NeonMind’s initial focus is on one of the biggest health issues the world is facing right now: obesity. It’s an
epidemic that is responsible for 37% of the global burden of disease, according to the National Centre for
Biotechnology Information. NeonMind is exploring the use of psilocybin (a complex organic compound found
in psychedelic mushrooms) as a potential treatment for weight loss through a preclinical trial. It has hired the
University of British Columbia, which has been granted authorization by Health Canada to use Psilocybin in
NeonMind’s Preclinical Trial, to test the potential use of psilocybin to improve eating habits and cause weight
loss. The Preclinical Trial started in November 2020 and NeonMind expects to complete an application for a
Phase 2 Human Trial in the spring of 2021.
NeonMind has filed 5 US provisional patent applications claiming methods of aiding in weight loss, treating
compulsive eating disorder, treating obesity or a complication of obesity, and/or altering the diet of an individual
2/2
by administering psilocybin and/or other psychedelic compounds or their analogs or by administering psilocybin
or its analog in conjunction with therapy or other treatments.
NeonMind is also pursuing commercialization of its catalogue of proprietary medicinal mushroom product
formulas. It recently launched a collection of four mushroom infused coffees which are infused with medicinal
mushrooms Lion's Mane, Turkey Tail, Reishi and Cordyceps. The NeonMind eCommerce platform launched in
November 2020 at www.neonmind.com for direct to consumer sales of these products.
"Our public listing is a significant milestone for us as we execute on our plan to grow our intellectual property
portfolio and product development pipeline," says NeonMind founder and CEO, Penny White, "We are
extremely grateful to the investment community for their participation in our successful public offering and we
look forward to strategically increasing shareholder value as we advance our business in the psychedelic sector."
As part of NeonMind's disclosure obligations as a reporting issuer, ongoing financial and material filings can be
found on the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.
For more information on NeonMind, go to www.NeonMindbiosciences.com or buy NeonMind mushroom
infused coffee at www.NeonMind.com.
Penny White, President & CEO
604 617 7979
The Exchange has not reviewed, approved or disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These statements
relate to future events or NeonMind's future performance. The use of any of the words "could", "expect",
"believe", "will", "projected","estimated" and similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information and are based on NeonMind's current belief
or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In
particular, NeonMind's stated use of proceeds and its expectation as to the continuation of its preclinical trial,
development of its intellectual property and other steps in its drug development. constitute forward-looking
information. Actual results and developments may differ materially from those contemplated by forward-looking
information. Readers are cautioned not to place undue reliance on forward-looking information. The statements
made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to
publicly update or revise any forward-looking information, whether as a result of new information, future events
or otherwise, except as may be expressly required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/71280